Haemonetics Corporation $HAE Shares Purchased by Invenomic Capital Management LP

Invenomic Capital Management LP boosted its stake in Haemonetics Corporation (NYSE:HAE) by 1,691.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 498,317 shares of the medical instruments supplier’s stock after acquiring an additional 470,502 shares during the quarter. Haemonetics comprises about 1.2% of Invenomic Capital Management LP’s holdings, making the stock its 21st largest holding. Invenomic Capital Management LP owned approximately 1.06% of Haemonetics worth $24,288,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its stake in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the period. Versant Capital Management Inc increased its stake in Haemonetics by 216.4% during the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 567 shares during the period. Byrne Asset Management LLC purchased a new stake in Haemonetics during the 3rd quarter worth $42,000. Elevation Point Wealth Partners LLC acquired a new position in Haemonetics in the 2nd quarter worth $64,000. Finally, Hantz Financial Services Inc. boosted its position in Haemonetics by 792.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock valued at $55,000 after buying an additional 998 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HAE. Needham & Company LLC cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. Weiss Ratings restated a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. Robert W. Baird set a $81.00 target price on Haemonetics in a research note on Friday, February 6th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Finally, Mizuho cut their price target on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $83.89.

Haemonetics Stock Performance

HAE opened at $59.93 on Monday. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01. The business’s 50 day moving average is $66.67 and its 200-day moving average is $64.79. The stock has a market cap of $2.78 billion, a PE ratio of 16.51, a price-to-earnings-growth ratio of 1.25 and a beta of 0.28. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.